Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Not applicable Interventional

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NCT02621593
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 14, 2026, 7:13 PM EDT
Withdrawn Not applicable Interventional

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

NCT05121493
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed No phase listed Observational

AONDA Therapeutic Indication Study I

NCT05891106
View directory record Official record
Conditions
Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy, Corneal Ulcer, Foreign Body in Cornea, Bell Palsy, Keratoconjunctivitis, Filamentary Keratitis, Sicca Syndrome; Keratoconjunctivitis (Etiology)
Interventions
Lotrafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Franklin Park, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 14, 2026, 7:13 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Prospective Study to Validate the Imaging Biomarker for NCP (R33)

NCT05653921
View directory record Official record
Conditions
Dry Eye Syndromes, Corneal Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

NCT05322148
View directory record Official record
Conditions
Dry Eye
Interventions
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Hemet, California • Laguna Hills, California • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 14, 2026, 7:13 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®

NCT07722624
View directory record Official record
Conditions
Dry Eye
Interventions
Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo®
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893
View directory record Official record
Conditions
Dry Eye
Interventions
Tyrvaya
Drug
Lead sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

NCT03417505
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
Device
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

NCT03982368
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

NCT04498468
View directory record Official record
Conditions
Dry Eye
Interventions
Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 14, 2026, 7:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Corneal Epithelial Thickness Mapping

NCT01712022
View directory record Official record
Conditions
Dry Eye and Contact Lens Wear
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • Latham, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 3 Interventional

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05350072
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Van Nuys, California • Tamarac, Florida • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

MiBo ThermoFlo Lid Temperature Evaluation

NCT03787212
View directory record Official record
Conditions
Dry Eye
Interventions
MiBo ThermoFlo, Bruder Mask
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 4 Interventional

Treatment Regimens in Meibomian Gland Dysfunction

NCT05594745
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast Ophthalmic, Systane Free, Lipiflow
Drug · Device
Lead sponsor
Tauber Eye Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Phase 4 Interventional

Performance of Systane PRO Versus Refresh Optive Mega-3

NCT06975891
View directory record Official record
Conditions
Dry Eye
Interventions
Systane PRO, Refresh Optive MEGA-3
Drug
Lead sponsor
Scripps Poway Eyecare and Optometry
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed Eye Neutrophils in Dry Eye Disease

NCT03332342
View directory record Official record
Conditions
Dry Eye, Ocular Inflammation
Interventions
Eye wash
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 14, 2026, 7:13 PM EDT
Completed No phase listed Observational

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

NCT03327870
View directory record Official record
Conditions
Sjogren's Syndrome, Oral Health
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 14, 2026, 7:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1Phase 2 Interventional

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

NCT01369589
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
P-552, Placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 14, 2026, 7:13 PM EDT
Completed Phase 3 Interventional

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

NCT00471419
View directory record Official record
Conditions
Dry Eye
Interventions
Rimexolone
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 14, 2026, 7:13 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Nutrition Impact on Tear Film

NCT01561040
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega 3, Vitamins A, D3 and E
Dietary Supplement
Lead sponsor
Eye and Vision Technologies and Research Institute
Network
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Conifer, Colorado • Oak Lawn, Illinois • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 14, 2026, 7:13 PM EDT
Terminated Not applicable Interventional Results available

Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

NCT03502447
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
TearCare, Warm Compress and Lid Massage
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Laguna Hills, California • Newport Beach, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 14, 2026, 7:13 PM EDT